NFE2L2 and neoplasm: SFN reduces tumor growth by 31% and lowers the proliferating potential of breast CSCs. SFN also reduces areas of necrosis and causes a modification of immune cell type infiltration, thus reducing metastasis of cancer cells. SFN inhibits cancer cell migration particularly in TNBC primary tumor by activating Nrf2 and enhancing the secretion of neurophils. SFN lowers the survival rate to 65% when administered at concentrations of 250 μM but does not cause hormetic action at lower doses. SFN suppresses the spread of CSCs released by TNBC primary tumors